API Manufacturing Lonza Completes Laboratory Expansion in China

Source: Press release

Lonza has expanded its API development and manufacturing laboratories in Nansha, China. The cGMP manufacturing laboratories are expected to provide additional early-phase highly-potent API manufacturing capabilities for the company.

Related Vendors

HPAPIs currently form a large part of Lonza’s small molecule development pipeline and the demand for manufacturing is growing.
HPAPIs currently form a large part of Lonza’s small molecule development pipeline and the demand for manufacturing is growing.
(Source: Lonza)

Basel/Switzerland – Lonza has recently announced the completion of a laboratory expansion at its active pharmaceutical ingredients (API) manufacturing site at Nansha, China. The expansion focused on extending the capabilities and capacity of development laboratories and kilogram-scale cGMP manufacturing laboratories for clinical supply of highly-potent APIs (HPAPI).

HPAPIs represent a growing part of the small molecules pipeline with special requirements related to equipment, process safety, containment, and facility design. HPAPIs currently form a large part of Lonza’s small molecule development pipeline and the demand for manufacturing is growing. The new laboratories are part of the recent investment to expand the mid-scale manufacturing capacity at the Nansha (CN) site and add additional capabilities in Lonza’s global HPAPI manufacturing network to meet growing customer demand.

Stay up to Date

Do you want the latest news, specialist articles and information on new products? Then you can register for our free newsletter:

Choose your Newsletter

Jan Vertommen, Executive Director, Commercial Development, Small Molecules, Lonza commented: “With over 1000 HPAPIs in development across multiple indications, there is a growing need for HPAPI development and manufacturing capacity from early-phase to commercial. The new laboratories further strengthen our global HPAPI manufacturing offering, and we are pleased that the first European and US-headquartered customers have signed HPAPI programs for our new laboratories in Nansha.”

The laboratory capabilities will increase the laboratory footprint to 250 m2 and will be equipped with state-of-the-art analytical and manufacturing equipment. The new laboratories will begin operations in March 2022.

Jason Zhang, R&D Director, Small Molecules API, Lonza, added: “The expansion of our HPAPI capabilities at Nansha enables us to enter HPAPI manufacturing to meet growing global demand, especially in supporting clinical trials in oncology. Our presence in Nansha allows us to leverage world-class, high-quality and reliable local suppliers of raw materials, thus further increasing the speed of problem-solving and manufacturing.”

The expanded capabilities at the Nansha site will continue to support the development and manufacture of innovative treatments for our global customers and their patients.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent

(ID:48086041)